MX2014002223A - Method for treating auto-immune diseases for creating anti-bodies and strengthening the immune system. - Google Patents
Method for treating auto-immune diseases for creating anti-bodies and strengthening the immune system.Info
- Publication number
- MX2014002223A MX2014002223A MX2014002223A MX2014002223A MX2014002223A MX 2014002223 A MX2014002223 A MX 2014002223A MX 2014002223 A MX2014002223 A MX 2014002223A MX 2014002223 A MX2014002223 A MX 2014002223A MX 2014002223 A MX2014002223 A MX 2014002223A
- Authority
- MX
- Mexico
- Prior art keywords
- pathogen
- immune system
- cells
- immune
- immunological memory
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The adaptive immune system allows a higher immune response to be obtained, as well as the establishment of the immunological memory, where each pathogen is remembered by an antigen characteristic of this pathogen in particular. The adaptive immune system allows a higher immune response to be obtained, as well as the establishment of the immunological memory, where each pathogen is remembered by an antigen characteristic of this pathogen in particular. This response generates immunological memory producing, in most cases, permanent immunity against the disease. The cells of the adaptive immune system are a special class of leukocytes, known as lymphocytes. The B and T cells are the main class of lymphocytes and result from pluripotent hematopoietic stem cells. The B and T cells contain receptor molecules that recognize specific targets. The T cells recognize a strange target, as a pathogen, manly after the antigens (small fragments of pathogens) have been processed and presented in com bination with an own receptor. Included is a normal saline solution of 80% to 90% exclusively for being used in tissue culturing, which is sterilized by the membrane and free of pyrogens. All these components are mixed in an amber glass container of 100ml, with 50 ml of solution under a range of 40 ml to 60 ml.
Description
METHOD FOR THE TREATMENT OF SELF-IMMUNE DISEASES TO CREATE ANTI-ANTIBODIES AND STRENGTHEN THE IMMUNE SYSTEM
BACKGROUND
In the medical field, it has been determined that it is logical to take advantage of the patient's own blood to use the auto antibodies as true antigens and thus stimulate the immune system to produce normal antibodies that block and destroy the auto antibodies.
The soluble antibodies are secreted by an activated B lymphocyte ^ its plasma cell form) to bind to foreign substances and signal them for destruction by the rest of the immune system.
They could also be called free antibodies to autoimmune diseases are caused by an antibody that by a defect of the immune system is released from the cell and attacks the immune system itself should defend
Specific for Pénfigo vulgar.Miastenia gravis organ. Thyroiditis of Hashlmoto.MIxedema prlmario.Silver disease Miller-Fisher syndrome. Myasthenia of Lambert-Eaton. Sympathetic ophthalmia. Neuropatiasüveitis. asthma. Primary biliary cirrhosis. Sclerosing cholangitis primary autoimmune hepatitis, celiac disease, gastric atrophy, pernicious anemia,
Diabetes mellitus type 1, Diabetes mellitus type 2, Crohn's disease, Ulcerative colitis, Goodpasture syndrome.
Multiorganic or systematic Multiple sclerosis, Devic's disease, Amyotrophic lateral sclerosis, PsoriasisVitiligo, Wegener's granulomatosis, Beh et's disease, Systemic vasculitis, Chronic fatigue syndrome, Fibromyalgia, Multiple sclerosis Devic's disease, Amyotrophic lateral sclerosis, Psoriasis, Vitiligo granulomatosis Wegener, Behget's disease, Systemic vasculitis, Chronic fatigue syndrome, Fibromyalgia. Immune compromised patients (low immune system) in patients with diseases such as cancer, human papilloma virus, C hepatitus, and HIV virus (carriers) b or (AIDS) Acquired Immune Deficiency Syndrome.
Traditionally autoimmune diseases are treated with corticosteroids are hormones of the group of steroids (produced by the cortex of the adrenal glands) and their derivatives
Corticosteroids are implicated in a variety of physiological mechanisms, including those that regulate inflammation, the immune system, carbohydrate metabolism, protein catabolism, plasma electrolyte levels and, finally, those that characterize the response to stress
DESCRIPTION
It is possible to take advantage of the patient's own blood to use the auto-antibodies as true antigens and thus stimulate their Immune System to produce normal antibodies that block and destroy the auto-antibodies.
5 to 6 milliliters of intravenous blood are removed in a range of 1 to 10. This blood is inoculated into a tissue culture substance in a 100-milliliter flask with 50 milliliters of normal saline, 0.85% membrane-sterilized, for exclusive use for tissue culture.
Immediate agitation or suction, (manual or machine) to break the red blood cells, a procedure known as hematolysis, is performed at more than 1000 revolutions per minute, the erythrocytes are lysed and the antigens are released on the surface
Thermal shock is performed at 4 ° C for a time understood depending on the type of disease of the patient, sedimented for 24 hours. Before the first application
An autovaccine is obtained with its own antigens, now transformed into cold antibodies, for all diseases of auto-immune origin and not only patients receiving immune cell therapy and who are healthy, significantly improve their immune system.
With 6 milliliters of blood, 52 doses can be obtained so that later they can be administered in the indicated doses, depending on the specific disease. It can be applied 2 or 3 times a day.
It is wicked and does not produce side effects so it is not aggressive to the patient.
They can be applied up to 15 to those without collateral or secondary effects. This solution is re injected to the patient in specific doses and periods, in the abdomen exclusively with insulin syringe, the antigens to be released and cultured transform the molecule into true ANTI-ANTIBODIES
The anti-antibodies by their transformation and molecular weight have the ability to adapt to the immunological memory, this produces a response that improves the immune system and strengthens B and T lymphocytes
The antibody that became self-antigen, now transformed into anti-antibody is the most applicable method to generate auto-immune memory.
At the end of the first treatment of 52 doses depending on the duration (may be 28 days) The patient will go to perform the second to a, blood for the proportion of 2 doses until the doctor determines the time and duration of it, the treatment of each patient in his own home in refrigeration at 6 degrees Celsius or less without reaching the freezing point.
Symptoms and Side Effects
There are no reports of side effects since it is the patient's own blood, there is a reduction in the consumption of control medications, as well as greater energy thanks to the strengthening of B and T lymphocytes.
Weight reduction is achieved as it acts as a detoxifier of the immune system in addition to significant reduction of common symptoms of the disease.
Claims (4)
1. A method for the treatment of auto-immune diseases to create anti-bodies and strengthen the immune system, by obtaining antigens upon release and cultivation transform the molecule into true ANTI-ANTIBODIES comprising the following steps:
2. Claim 1 and the anti-antibodies by their transformation and molecular weight have the ability to adapt to the immunological memory.
3. Claim 1 strengthens B and T lymphocytes.
4. Claim 1, the antibody that was transformed into autoantigen, now transformed into anti-antibody is the most applicable method for generating auto-immune memory.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2014002223A MX2014002223A (en) | 2014-02-25 | 2014-02-25 | Method for treating auto-immune diseases for creating anti-bodies and strengthening the immune system. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2014002223A MX2014002223A (en) | 2014-02-25 | 2014-02-25 | Method for treating auto-immune diseases for creating anti-bodies and strengthening the immune system. |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014002223A true MX2014002223A (en) | 2015-08-25 |
Family
ID=54598933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014002223A MX2014002223A (en) | 2014-02-25 | 2014-02-25 | Method for treating auto-immune diseases for creating anti-bodies and strengthening the immune system. |
Country Status (1)
Country | Link |
---|---|
MX (1) | MX2014002223A (en) |
-
2014
- 2014-02-25 MX MX2014002223A patent/MX2014002223A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | GLIS, a bioactive proteoglycan fraction from Ganoderma lucidum, displays anti-tumour activity by increasing both humoral and cellular immune response | |
CN106589133A (en) | Preparation and applications of liver-cancer-specific CTL cells induced by new enhanced antigen combined polypeptide | |
Schepici et al. | Regenerative effects of exosomes-derived MSCs: an overview on spinal cord injury experimental studies | |
CN107557333A (en) | A kind of neoantigen for cell therapy is in the preparation method of delivery cell | |
Han et al. | The critical role of therapeutic plasma exchange in ABO-incompatible liver transplantation | |
MX2014002223A (en) | Method for treating auto-immune diseases for creating anti-bodies and strengthening the immune system. | |
EP3148574B1 (en) | Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus | |
JP2019508458A5 (en) | ||
Qi et al. | P. aeruginosa mediated necroptosis in mouse tumor cells induces long-lasting systemic antitumor immunity | |
Siegel et al. | Multiple cranial neuropathies from nivolumab in a patient with metastatic hepatocellular carcinoma | |
EP4306128A3 (en) | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) | |
CN107028982A (en) | Human plactnta hepatitis B specific immune activity polypeptide | |
US20160340650A1 (en) | Blood derived immune stimulatory compositions | |
Martínez-Alcantar et al. | Anterior chamber associated immune deviation to cytosolic neural antigens avoids self-reactivity after optic nerve injury and polarizes the retinal environment to an anti-inflammatory profile | |
Wu et al. | Effects of bone marrow mesenchymal stem cells on the cardiac function and immune system of mice with endotoxemia | |
Kim et al. | Relapse of minimal change disease following infection with the 2009 pandemic influenza (H1N1) virus | |
WO2017142014A1 (en) | Drug for inflammatory disease | |
Barabas et al. | Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique | |
TW201420130A (en) | Liquid agent containing dissolved carbon dioxide and administrating method thereof | |
Sung et al. | Polysaccharide extracted from Sargassum fulvellum leads to macrophage activation and Th1 polarization in splenocytes | |
RU2585097C1 (en) | Method of treating chronic pancreatitis | |
RU2013110503A (en) | METHOD AND DEVICE FOR TREATING DISORDERS RELATED TO THE CHOLESTEROL LEVEL IN BLOOD | |
RU2755638C2 (en) | Method for increasing antitumour resistance, antioxidant and immunostimulating effects on the body | |
Vázquez et al. | New therapeutic alternatives for severe sepsis in the critical patient. A review | |
RU2682320C1 (en) | Means for the prevention of viral infections |